Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Professional Essentials · True Rheumatic Emergencies · Free · No registration

Catastrophic antiphospholipid syndrome

Recognize rapidly spreading thrombotic injury, distinguish urgent mimics and coordinate anticoagulation with immune and organ support.

Clinically reviewed: October 4, 2026 · Free to read · English

1. Recognize spreading vascular injury

Catastrophic antiphospholipid syndrome (CAPS) is an uncommon, life-threatening APS presentation in which thrombosis and microvascular injury produce rapidly accumulating organ dysfunction. Kidney, brain, lung, heart and skin may become involved over days. A known APS diagnosis strengthens suspicion, but CAPS can be the first presentation. Visible large-vessel thrombosis is not required.

Create a brief organ-and-time map: baseline function, first new symptom, each additional organ event and current support requirements. Acute kidney injury with falling platelets becomes more concerning when new confusion, ischemic skin lesions or hypoxemia are placed on the same timeline. Infection, surgery, pregnancy and interrupted anticoagulation may trigger deterioration; they are clues rather than diagnostic requirements.

Suspected CAPS needs immediate hospital assessment with hematology, rheumatology and critical care. Shock, altered consciousness, focal neurologic deficit, cardiac ischemia, severe hypoxemia or threatened tissue requires emergency escalation. Do not wait for a third organ, a safe biopsy opportunity or repeat antibodies before acting on a compelling, deteriorating syndrome.

Recognition and organ chronology → Professional access required

2. Stabilize, sample and identify the trigger

Assess airway, oxygenation, perfusion, neurologic state, urine output and active bleeding. Obtain blood count and platelet trend, smear, hemolysis markers, kidney and liver tests, PT/aPTT, fibrinogen and D-dimer. Add cultures, ECG, troponin and imaging directed at the threatened organ. The purpose is to identify treatable injury now, not to collect every possible test before treatment.

Send lupus anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies, and retrieve previous results. Anticoagulants and the acute illness can complicate lupus-anticoagulant interpretation. An isolated positive antiphospholipid antibody is not proof of CAPS. Persistence is assessed later when appropriate; the repeat-testing interval is not a waiting period for emergency care.

Investigate infection and obtain source control when indicated. Review anticoagulant interruption, adherence, recent procedures, pregnancy/postpartum status and all heparin exposure, including flushes. Biopsy can support microvascular attribution when safe and management-relevant. Hazardous tissue sampling solely to satisfy classification is inappropriate.

Initial assessment and diagnostic sampling → Professional access required

3. Act on competing emergencies

Thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT), sepsis with disseminated intravascular coagulation, complement-mediated thrombotic microangiopathy and severe hypertension may resemble CAPS. More than one process can coexist. A positive antiphospholipid test should not shut down these pathways.

With high TTP suspicion, obtain ADAMTS13 samples before plasma exchange or blood products when feasible and initiate urgent TTP-directed care without waiting for the result. ISTH guidance supports immediate plasma exchange and glucocorticoids in this setting; hematology determines caplacizumab and other immunotherapy. Severe ADAMTS13 deficiency strongly supports TTP.

Apply an established HIT probability assessment. With intermediate or high probability, ASH guidance supports stopping heparin and using the appropriate non-heparin pathway while testing proceeds. Replacing unfractionated heparin with low-molecular-weight heparin does not solve HIT.

Systemic sclerosis with new hypertension and AKI requires assessment for renal crisis. Pregnancy-related microangiopathy and HELLP require maternal-fetal medicine input. These alternatives can change immediate treatment, including whether high-dose glucocorticoids or heparin are appropriate.

TTP, HIT and other urgent alternatives → Professional access required

4. Coordinate combination treatment

For sufficiently strong CAPS suspicion, treatment may begin before every confirmatory result is available. McMaster CAPS guidance and EULAR APS recommendations support therapeutic anticoagulation, glucocorticoids, and plasma exchange and/or intravenous immunoglobulin (IVIG), together with treatment of precipitating factors and organ support. Steroids alone do not replace this coordinated approach.

Unfractionated heparin is often useful initially because it can be adjusted rapidly in an unstable patient or around procedures. Actual choice and intensity require review of bleeding, suspected HIT, organ function and prior anticoagulants. A prophylactic regimen is not equivalent to therapeutic treatment. No platelet number in isolation automatically determines whether anticoagulation is safe.

Arrange apheresis early when indicated, particularly with prominent microangiopathic injury. The team should agree exchange frequency, replacement fluid, vascular access and stopping criteria. If IVIG is used, renal function, fluid burden, thrombotic risk and product formulation matter. Coordinate timing so exchange does not immediately remove a recently administered therapeutic agent.

The CAPS registry treatment analysis associated triple therapy with lower mortality than other combinations. This was observational evidence, subject to selection and confounding; it does not prove equivalence between exchange and IVIG or supply a universal regimen.

Combination treatment and evidence limits → Professional access required

5. Avoid anticoagulation and laboratory traps

A prolonged baseline aPTT can reflect lupus anticoagulant rather than protection from thrombosis. Using it as a simple measure of heparin effect may lead to undertreatment. The 2024 BSH APS guideline recommends heparin anti-Xa monitoring in CAPS. Agree assay calibration, target and sampling schedule with the laboratory.

Recent direct factor Xa inhibitors can interfere with heparin anti-Xa interpretation. Record the drug, last dose and kidney function; communicate uncertainty before adjusting an infusion to a potentially misleading result. Drug lists and one clotting measurement cannot establish adequate anticoagulation.

Active major bleeding, including alveolar hemorrhage, creates an immediate competing-risk decision. Stabilize and address the bleeding source while critical care and hematology decide interruption, reversal and resumption. Document who will reassess and what findings will change the plan. Thrombocytopenia without major bleeding should not automatically terminate all antithrombotic care.

Do not add aspirin by default or substitute a direct oral anticoagulant as an established acute CAPS regimen. Long-term anticoagulant choice also depends on the arterial/venous history and antibody profile.

Monitoring heparin and balancing bleeding → Professional access required

6. Reassess response and plan ongoing care

Track new organ events, perfusion, oxygen support, urine output, platelet and hemolysis trends, bleeding and infection. A rising platelet count is encouraging but does not cancel a new stroke, ischemic limb or deteriorating kidney function. Refractory disease requires reassessment of attribution, adequacy of anticoagulation, ongoing triggers and treatment complications.

Rituximab or complement inhibition may be considered by an expert team in selected refractory CAPS; evidence remains limited. Eculizumab is off-label for CAPS and creates substantial meningococcal risk. CDC guidance emphasizes vaccination and individualized antimicrobial prevention; vaccination does not eliminate the risk.

After recovery, establish a durable anticoagulation plan, monitoring responsibility and strategies to prevent avoidable interruption around future procedures. Reassess antibody persistence and the underlying systemic disease, including lupus. Discuss residual organ injury, rehabilitation, pregnancy planning when relevant and rapid access for recurrent symptoms. Before declaring treatment failure, verify that the prescribed anticoagulant was actually delivered, the assay was interpretable and the trigger was addressed. Review new lesions with the relevant organ specialist; established infarction and ongoing thrombosis require different responses. If exchange, IVIG or advanced organ support is unavailable, discuss transfer early with the receiving center. Communicate active bleeding and the current anticoagulant explicitly so the transport and procedure plans account for both risks.

The discharge plan should identify the actual anticoagulant and target, interactions, bleeding instructions and the clinician coordinating follow-up.

Selected sources

Clinical review: October 4, 2026. This independent overview accompanies the full professional emergency module.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Rheumatology